

Dott.ssa Ester Orlandi

Medico Radioterapista

ATTIVITA' SCIENTIFICA

Official H index: 19.0; Scopus Author Id: 7005698929; ORCID ID: 0000-0001-6495-8574;
RESEARCH ID: B-9486-2017

Da 2017 ad oggi: Lecturer at the Radiotherapy Specialization School, Milan University, Milan.

Aprile 2018: Italian National Scientific licence for Associate Professorship (scientific Field- MED 36- Radiology, Radiation Oncology, Nuclear Medicine).

Marzo 2020: representative of the EORTC Head & Neck group for the new Radiation Oncology Scientific Council (ROSC).

Affiliazioni a Società Scientifiche

Membro della Associazione Italiana di Radioterapia Oncologica (AIRO), con parte attiva nel gruppo di lavoro AIRO testa collo. Già consigliere del gruppo (del gruppo AIRO Lombardia (2008-2010). Già consigliere del gruppo di lavoro AIRO testa-collo (2015-2017).

Membro della Società Europea di Radioterapia Oncologica (European Society for Radiotherapy and Oncology, ESTRO). Membro attivo di European Organization for Research and Treatment of Cancer (EORTC)-Head and Neck (H&N) Group.

Dal 13 marzo 2018 membro del ROG (Radiation Oncology Group) H&N-EORTC.

Da aprile 2019, Consigliere di AIOCC (Associazione Italiana Oncologia Cervico Cefalica).

Da 01-12-2015, membro del Comitato Editoriale della rivista "Tumori Journal" – Section Editor: Radiotherapy; Section Editor: Head and Neck Cancer.

Revisore per le seguenti riviste scientifiche. "Radiotherapy and Oncology", "Annals of Oncology", "European Journal of Cancer Care", "Radiation Oncology", "ACTA Otorhinolaryngologica Italica", "British Journal Cancer", "Physica medica", "Frontiers in Oncology", "Frontiers in Oncology".

Da Gennaio 2019 ad oggi Guest Editor insieme a Cesare Piazza e Laura Locati di un Orlandi E, Locati L) Special Issue in Cancers intitolato "Emerging Concepts in Treatment of Laryngeal Cancer."

Da giugno 2019 ad oggi Guest Editor insieme Tiziana rancati, Claudio Firino, Giuseppe Sanguineti, Riccardo Valdagni di un Special Issue in Frontiers in Oncology intitolato: "Modeling for Prediction of Radiation-Induced Toxicity to Improve Therapeutic Ratio in the Modern Radiation Therapy Era".

PUBBLICAZIONI SCIENTIFICHE

Articoli scientifici sottoposti a revisione critica indipendente (Peer Reviewed) pubblicati su riviste con Impact Factor:

1. Casanova M, Ferrari a, Gandola L, Orlandi E, Spreafico F, Terenziani M, Navarria P, Luksch R, Massimino M,. Cefalo G, Lombardi F, Fossati Bellani F.

"Undifferentiated nasopharyngeal carcinoma in children and adolescents: comparison between staging systems".
Ann Oncol, 2001;12: 1157-1162

2. Palazzi M, [Orlandi E](#), Pignoli E, Zonca G, Sangalli C, Stucchi C, Olmi P. ***"Target coverage and neck cancer treated with intensity modulated radiotherapy: A comparison with conventional and conformal techniques"*** Tumori, 2006; 92: 503-510
3. [Orlandi E](#), Zonca G, Pignoli E, Stucchi C, Borroni M, Collini P, Cantù G, Casali PG, Grosso F, Cerrotta A, Fallai C, Olmi P. ***"Postoperative radiotherapy for synovialsarcoma of the head and neck during pregnancy: clinical, technical management and fetal dose estimate"*** Tumori, 2007; 93: 45-52
4. Bossi P, Liberatoscioli C, Bergamini C, Locati L, Fava S, Rinaldi C, [Orlandi E](#), Olmi P, Tagliabue E, Ménard S, Licitra L. ***"Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients"*** Ann Oncol, 2007;18: 601-602
5. Palazzi M, Tomatis S, [Orlandi E](#), Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C, Licitra L, Scaramellini G, Cantù G, Olmi P. ***"Effects of Treatment Intensification on Acute Local Toxicity During Radiotherapy For Head and Neck Cancer: a Prospective Observational Study Validating CTCAE v3.0 Scoring System"*** Int J Rad Oncol Biol Phys, 2008; 70: 330-337
6. Fallai C, Perrone F, Licitra L, Pilotti S, Locati L, Bossi P, [Orlandi E](#), Palazzi M, Olmi P. ***"Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status"***. Int J Rad Oncol Biol Phys, 2009; 75: 1053-1059
7. [Orlandi E](#), [Palazzi M](#), [Pignoli E](#), [Fallai C](#), [Giostra A](#), [Olmi P](#). ***"Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review"***. Crit Rev Oncol Hematol, 2010;73: 111-125
8. [Palazzi M](#), [Orlandi E](#), [Bossi P](#), [Pignoli E](#), [Potepan P](#), [Guzzo M](#), [Franceschini M](#), [Scaramellini G](#), [Cantù G](#), [Licitra L](#), [Olmi P](#), [Tomatis S](#). ***"Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience"***. Int J Rad Oncol Biol Phys, 2009; 74: 774-780
9. Mongioj V, [Orlandi E](#), Palazzi M, Deponti E, Marzia F, Stucchi C, Sangalli C, Fallai C, Zonca G, Olmi P, Pignoli E. ***"Set-up errors analyses in IMRT treatments for nasopharyngeal carcinoma to evaluate time trends, PTV and PRV margins"***. Acta Oncol, 2011; 50:61-71
10. Bossi P, [Orlandi E](#), Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L. ***"Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer"***. Ann Oncol, 2011;22: 2495-500
11. Granata R, Miceli R, [Orlandi E](#), Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L, ***"Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study"***. Ann Oncol, 2012; 23:1832-7
12. Langer M, [Orlandi E](#), Carrara M, Previtali P, Haeusler EA. ***"Management of patients with implantable cardioverter defibrillator needing radiation therapy for cancer"*** Br J Anaesth, 2012; 108:881-2.
13. Naldi, G., Avuzzi, B., Fantini, S., Carrara, M., [Orlandi E](#), Assafra, E., Tomatis, S. ***"A segmentation problem in quantitative assessment of organ disposition in radiotherapy"***. Image Analysis and Stereology, 2011: 179-186.
14. [Orlandi E](#), Iannacone E, Fallai C, Bossi P, Licitra L. ***"Comments on "postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure" by Chan and Coll."*** Oral Oncol, 2013;49: e38
15. Bossi P, Perrone F, Miceli R, Cantù G, Mariani L, [Orlandi E](#), Fallai C, Locati LD, Cortelazzi B, Quattrone P, Potepan P, Licitra L, Pilotti S. ***"Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma."*** Oral Oncol, 2013: 49:413-9.

16. **Orlandi E**, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, Iannacone E, Guzzo M, Ibba T, Crippa F, Licitra L, Pignoli E, Fallai. **"Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma."** *Future Oncol*, 2013;9:103-14.
17. Bossi P, Numico G, De Santis V, Ruo Redda MG, Reali A, Belgioia L, Cossu Rocca M, **Orlandi E**, Airoidi M, Bacigalupo A, Mazzer M, Saibene G, Russi E. **"Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey"**. *Support Care Cancer*. 2014, 2014;22:1889-96
18. Bossi P, **Orlandi E**, Miceli R, Perrone F, Guzzo M, Mariani L, Granata R, Locati L, Fallai C, Cortelazzi B, Pilotti S, Scaramellini G, Gloghini A, Licitra L. **"Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis."** *Ann Oncol*, 2014;25:694-9.
19. Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, **Orlandi E**, Locati L, Scaramellini G, Fallai C, Licitra L **"Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial"**. *Ann Oncol*. 2014, 25:462-6.
20. Naldi G, Avuzzi B, Fantini S, Carrara M., **Orlandi E**, Assafra E, Tomatis S. **"A segmentation problem in quantitative assessment of organ disposition in radiotherapy"**. *Image Anal Stereo*, 2011;30:179-86.
21. Alterio D, Ciardo D, Preda L, Argenone A, Caspiani O, Micera R, Ruo Redda MG, Russi EG, Bianchi E, **Orlandi E**, Bacigalupo A, Busetto M, Cante D, Deantonio L, De Sanctis V, Franco P, Lastrucci L, Marucci L, Merlotti A, Molteni M, Pajar F, Rampino M, Santoro L, Ferrari A, Bazzani F, Caputo M, Laudati A, Borzillo V, Falivene S, Simoni N, Vigo F, Iannacone E, Reali A, Bonanni A, Leone M, Giannello L, Taglianti RV, Orecchia R. **"Contouring of the Pharyngeal Superior Constrictor Muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group"** *Radiother Oncol*. 2014;112:337-42.
22. **Orlandi E**, Takanen S, Giandini T, Iannacone E, Fontanella W, Locati L, Carrara M, Bossi P, Bergamini C, Granata R, Tombolini V, Ibba T, Licitra L, Pignoli E, Fallai C. **"Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review"**. [Future Oncol](#). 2014 Nov;10(14):2111-20.
23. **Orlandi E**, Giandini T, Iannacone E, De Ponti E, Carrara M, Mongioj V, Stucchi C, Tana S, Bossi P, Licitra L, Fallai C, Pignoli E. **"Radiotherapy for unresectable sinonasal cancers: Dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy"**. *Radiother Oncol*, 2014;113: 260-6.
24. Schindler A, Denaro N, Russi EG, Pizzorni N, Bossi P, Merlotti A, Spadola Bissetti M, Numico G, Gava A, **Orlandi E**, Caspiani O, Buglione M, Alterio D, Bacigalupo A, De Sanctis V, Pavanato G, Ripamonti C, Merlano MC, Licitra L, Sanguineti G, Langendijk JA, Murphy B. **"Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus"**. *Crit Rev Oncol Hematol*, 2015; 96:72-84.
25. Greco A, **Orlandi E**, Mirabile A, Takanen S, Fallai C, Iacovelli NA, Rimedio A, Russi E, Sala M, Monzani D, Rosenthal DI, Gunn GB, Steca P, Licitra L, Bossi P. **" Italian version of the M.D. Anderson Symptom Inventory-Head and Neck Module: linguistic validation"** *Support Care Cancer*, 2015;23:3465-72.
26. Bossi P, **Orlandi E**, Licitra L. **"Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base"**. *Br J Cancer*, 2015; 1;113:1638-9.
27. Buglione M, Cavagnini R, Di Rosario F, Sottocornola L, Maddalo M, Vassalli L, Grisanti S, Salgarello S, **Orlandi E**, Paganelli C, Majorana A, Gastaldi G, Bossi P, Berruti A, Pavanato G, Nicolai P, Maroldi R, Barasch A, Russi EG, Raber-Durlacher J, Murphy B, Magrini SM. **" Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement"** *Crit Rev Oncol Hematol*. 2016;97:131-42.
28. Salvatore S, Ripamonti CI, Marcegaglia S, **Orlandi E**, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi, Cristiana Bergamini R, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, Bossi P. **"Temporal course and predictive**

factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer.” Head Neck. 2016;38 Suppl 1:E1521-7.

29. Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, **Orlandi E**, Mariani L, Saibene G, Pilotti S, Licitra L. [**A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.**](#) Eur J Cancer. 2016; 69:158-165.

30. Bossi P, Bergamini C, Miceli R, Cova A, **Orlandi E**, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L. [**Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.**](#) Int J Radiat Oncol Biol Phys, 2016; 96:959-966.

31. Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordóñez B, Weinreb I, Bossi P, **Orlandi E**, Licitra LF, Song Y, O'Sullivan B, Siu LL, Kim J. [**Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.**](#) Eur J Cancer, 2016; 67:174-182.

32. **Orlandi E**, Iacovelli NA, Bonora M, Cavallo A, Fossati P. [**Salivary Gland. Photon beam and particle radiotherapy: Present and future.**](#) Oral Oncol, 2016; 60:146-56.

33. Buglione M, Cavagnini R, Di Rosario F, Maddalo M, Vassalli L, Grisanti S, Salgarello S, **Orlandi E**, Bossi P, Majorana A, Gastaldi G, Berruti A, Trippa F, Nicolai P, Barasch A, Russi EG, Raber-Durlacher J, Murphy B, Magrini SM. [**Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus \(Part 2\). Literature review and consensus statement.**](#) Crit Rev Oncol Hematol, 2016; 102:47-54.

34. Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, Imbimbo M, Fallai C, **Orlandi E**, Tana S, Iacovelli NA, Guzzo M, Ibba T, Colombo S, Bianchi R, Pizzi N, Fontanella W, Licitra L. [**Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?**](#) Oral Oncol, 2016; 54:54-7 .

35. Bossi P, Farina D, Gatta G, Lombardi D, Nicolai P, **Orlandi E**. [**Paranasal sinus cancer.**](#) Crit Rev Oncol Hematol. 2016; 98:45-61.

36. Iacovelli NA, [Naimo S](#), [Bonfantini F](#), [Cavallo A](#), [Bossi P](#), [Fallai C](#), [Pignoli E](#), [Alfieri S](#), [Bergamini C](#), [Favales F](#), **Orlandi E**. [**Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study.**](#) Support Care Cancer, 2017; 25:1787-1795.

37. Merlotti A, Mazzola R, Alterio D, Bacicalupo A, Bonomo P, Maddalo M, Alongi F, Russi E, **Orlandi E**. [**What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria.**](#) Crit Rev Oncol Hematol, 2017;111:20-30

38. Mercegaglia M, Alfieri S, Licitra L, Favales F, Mazzitelli D., **Orlandi E**, Bossi P [**Eliciting preferences for clinical follow-up in head and neck cancer patients best-worst scaling.**](#) Value Health, 2017; 20:799-808.

39. Alfieri S, Iacovelli NA, Marcegaglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, **Orlandi E**, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, Bossi P. [**Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.**](#) Oncotarget, 2017; 8: 47780-47789

40. **Orlandi E**, Bossi P. [**Towards a personalized cancer care for elderly head and neck cancer patients.**](#) Int J Rad Oncol Biol Phys, 2017;15;98:965-966

41. Alfieri S, **Orlandi E**, Bossi P. [**The Case Volume Issue in Head and Neck Oncology.**](#) Curr Treat Options Oncol, 2017; 27;18:65.

42. Resteghini C, Alfieri S, Quattrone P, Dominoni F, Garzone G, **Orlandi E**, Locati L, Bergamini C, Galbiati D, Iacovelli NA, Fallai C, Licitra L, Bossi P. **"RANK Expression In EBV Positive Nasopharyngeal Carcinoma Metastasis: A Ready-To-Treat Target?"**. *Oncotarget*, 2017 Oct 16;8:96184-96189.
43. **Orlandi E**, Licitra L. **"Personalized medicine: contradictions and limits of first-generation de-escalation trials in HPV- positive oropharyngeal cancer patients"**. *JAMA Otolaryngol Head Neck Surg*, 2018 ;144:99-100.
44. Bossi, Granata, **Orlandi E**, Licitra L, **"Comment on 'Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer'"**. *Br J Cancer*, 2018; 118(3):e5.
45. Iacovelli NA, Galaverni M, Cavallo A, Naimo S, Facchinetti S, Iotti C, Fallai C, **Orlandi E**. **"Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review"**. *Future Oncology*, 2018;14:291-305.
46. Resteghini C, Perrone F, Miceli R, Bergamini S, Alfieri S, **Orlandi E**, Guzzo M, Galbiati D, Cavalieri S, Locati L, Licitra L, Bossi P. **"PIK3CA and TP53 Prognostic role in HPV negative oropharyngeal cancers"**. *Tumori*. 2018 Jun;104(3):213-220
47. Maddalo M, Bonomo P, Belgioia L, Bacigalupo A, Donato V, Alterio D, **Orlandi E**, Argenone A, Merlotti A, Musio D, Trignani M, Ursino S, Arcangeli S, Furlan C, Osti MF; Italian Association of Radiation Oncology (AIRO). **"Re-irradiation with curative intent in patients with squamous cell carcinoma of the head and neck: a national survey of usual practice on behalf of the Italian Association of Radiation Oncology (AIRO)"**. *Eur Arch Otorhinolaryngol*. 2018; 275:561-567.
48. Bossi P, Miceli R, Granata R, Naimo S, Infante G, Locati LD, Iacovelli NA, Fallai C, Licitra L, **Orlandi E**. **Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges"**. *Int J Radiat Oncol Biol Phys*. 2018; 100: 1217-1221.
49. **Orlandi E**, Alfieri S, Simon C, Trama A, Licitra L; RARECAREnet Working Group. **"Treatment challenges in and outside a network setting: Head and neck cancers."** *Eur J Surg Oncol*. 2018 pii: S0748-7983(18)30417-7.
50. Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, **Orlandi E**, Guzzo M, Granata R, Galbiati D, Cavalieri S, Locati L, Licitra L, Bossi P. **"Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers."** *Tumori*. 2018 Jun;104(3):213-220.
51. Bonomo P, Merlotti A, Olmetto E, Bianchi A, Desideri I, Bacigalupo A, Franco P, Franzese C, **Orlandi E**, Livi L, Caini S. **"What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis."** *Eur J Nucl Med Mol Imaging*. 2018 Nov;45(12):2122-2138.
52. **Orlandi E**, Miceli R, Infante G, Mirabile A, Alterio D, Cossu Rocca M, Denaro N, Vigna-Taglianti R, Merlotti A, Schindler A, Pizzorni N, Fallai C, Licitra L, Bossi P. **"Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer."** *Dysphagia*. 2019 Feb;34(1):52-62.
53. Resteghini C, Trama A, Borroni E, Hosni H, Corrao G, **Orlandi E**, Calareso G, De Cecco L, Piazza C, Mainardi L, Licitra L. **"Big Data in Head and Neck Cancer."** *Curr Treat Options Oncol*. 2018 Oct 25.
54. **Orlandi E**, Iacovelli NA, Rancati T, Cicchetti A, Bossi P, Pignoli E, Bergamini C, Licitra L, Fallai C, Valdagni R, Cavallo A. **"Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients."** *Oral Oncol*. 2018 Nov;86:266-272.
55. Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, Bossi P, Alfieri S, Serafini G, Colombo CB, Cicchetti A, Mira M, Licitra L, Fallai C, Crippa F, **Orlandi E**. **"Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy."** *Radiol Med*. 2018 Dec 17.

56. Bresciani L, **Orlandi E**, Piazza C. **"Radiation-induced papillary thyroid cancer: is it a distinct clinical entity?"**. Curr Opin Otolaryngol Head Neck Surg. 2019 Apr;27(2):117-122.
57. Bossi P, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, **Orlandi E**, Guzzo M, Bianchi R, Ferella L, Infante G, Miceli R, Licitra L, Ripamonti CI. **"Prevalence of Fatigue in Head and Neck Cancer Survivors."** Ann Otol Rhinol Laryngol. 2019 Jan 30;3489419826138.
58. Siano M, Alfieri S, Granata R, Calareso G, **Orlandi E**, Bergamini C, Locati LD. **"The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment."** Tumori. 2019 Feb 19;300891619829571.
59. De Cecco L, Serafini MS, Facco C, Granata R, **Orlandi E**, Fallai C, Licitra L, Marchesi E, Perrone F, Pilotti S, Quattrone P, Piazza C, Sessa F, Turri-Zanoni M, Battaglia P, Castelnuovo P, Antognoni P, Canevari S, Bossi P. **"A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes."** Oral Oncol. 2019 Mar;90:94-101.
60. Trignani M, Argenone A, Di Biase S, Musio D, Merlotti A, Ursino S, **Orlandi E**, Genovesi D, Bacigalupo A. **"Inter-observer variability of clinical target volume delineation in definitive radiotherapy of neck lymph node metastases from unknown primary. A cooperative study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Group."** Radiol Med. 2019 Jul;124:682-692.
61. Bonomo P, Greto D, Desideri I, Loi M, Di Cataldo V, **Orlandi E**, Iacovelli NA, Becherini C, Visani L, Salvestrini V, Mariotti M, Livi L. **"Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: is the deferral of systemic therapy a potential goal?"** Oral Oncol. 2019 Jun;93:1-7. doi: 10.1016/j.oraloncology.2019.04.006. Epub 2019 Apr 8.
62. **Orlandi E**, Licitra L. **"The day after De-ESCALaTE and RTOG 1016 trials results"**. Future Oncol. 2019 Jun;15(18):2069-2072. doi
63. Imbimbo M, Alfieri S, Botta L, Bergamini C, Gloghini A, Calareso G, **Orlandi E**, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, Bossi P. **"Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up"**. Otolaryngol Head Neck Surg. 2019 Jul 9;194599819860808. doi: 10.1177/0194599819860808.
64. **Orlandi E**, Iacovelli NA, Cavallo A, Resteghini C, Gandola L, Licitra L, Bossi P. **"Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?"** Head Neck. 2019 Jul 17. doi: 10.1002/hed.25848
65. **Orlandi E**, Cavalieri S, Resteghini, Locati L, Licitra L, Castelnuovo P, Nicolai P, Piazza C, Paolo Bossi, **"Locally advanced epithelial sinonasal tumors: the impact of multimodal approach"**. Accepted for publication in The Laryngoscope
Article ID: LARY28202 Article DOI: 10.1002/lary.28202
66. Laura Locati, Mara Serena Serafini, Maria Federica Ianno', Andrea Carenzo, **Ester Orlandi**, Carlo Resteghini, Stefano Cavalieri, Paolo Bossi, Silvana Canevari, Lisa Licitra, Loris De Cecco **"Mining of self-organizing map gene-expression portraits reveals prognostic stratification of HPV-positive Head and Neck Squamous cell carcinoma"**. Cancers (Basel). 2019 Jul 26;11(8). pii: E1057
67. Lezizia Ferella, Anna Cavallo, Rosalba Miceli, Nicola Alessandro Iacovelli, Tommaso Giandini, Emanuele Pignoli, Giuseppina Calareso, Paolo Bossi, Carlo Resteghini, Giovanni Luca Gravina, Piero Nicolai, Paolo Castelnuovo, Cesare Piazza, Lisa Licitra, Carlo Fallai, **Ester Orlandi**. **"Prognostic role of primary tumor, nodal neck and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy"** Tumori. 2019 Aug 27;300891619868006. doi: 10.1177/0300891619868006
68. Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, **Orlandi E**, Mariani L, Licitra L. **"Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract"**. Head Neck. 2019 Oct;41(10):3670-3676.

69. **Orlandi E**, Bonomo P, Ferella L, D'Angelo E, Maddalo M, Alterio D, Infante G, Bacigalupo A, Argenone A, Iacovelli NA, Desideri I, Meduri B, Triggiani L, Volpe S, Belgioia L, Dionisi F, Romanello DA, Fallai C, Miceli R. "[Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: A multi-institutional study of AIRO-Head and Neck working group.](#)" *Head Neck*. 2019 Oct;41(10):3684-3692.

70 Ivaldi E, Di Mario D, Paderno A, Piazza C, Bossi P, Iacovelli NA, Incandela F, Locati L, Fallai C, **Orlandi E**. "[Postoperative radiotherapy \(PORT\) for early oral cavity cancer \(pT1-2,N0-1\): A review](#)". *Crit Rev Oncol Hematol*. 2019 Nov;143:67-75...

71. Dionisi F, Fiorica F, D'Angelo E, Maddalo M, Giacomelli I, Tornari E, Rosca A, Vigo F, Romanello D, Cianchetti M, Tommasino F, Massaccesi M, **Orlandi E**. "[Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review.](#)" *Oral Oncol*. 2019 Nov;98:35-4

72. **Orlandi E**, Iacovelli NA, Tombolini V, Rancati T, Polimeni A, De Cecco L, Valdagni R, De Felice F. "[Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer.](#)" *Oral Oncol*. 2019 Nov 1;99:104453.

73. Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, Bossi P, **Orlandi E**, Resteghini C, Platini F, Granata R, Quattrone P, Mancinelli M, Mariani L, Lo Vullo S, Licitra LF. "[Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.](#)" *Cancer*. 2020 Feb 7. doi: 10.1002/cncr.32754.

74. Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, **Orlandi E**, Platini F, Locati L, Giacomelli L, Licitra L, Bossi P. "[Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.](#)" *Drugs Context*. 2019 Dec 19;8:212611. doi: 10.7573/dic.212611. eCollection 2019

Capitoli di libro

1. **Orlandi E**, Bossi P. "**Carcinoma del rinofaringe**" (Capitolo n. 22 da p.293 a 307).

In "Tumori della testa e del collo: integrazione terapeutica nella conservazione della funzione d'organo". Editor: Lisa Licitra, Patrizia Olmi (Springer). 2011

2. Locati LD, Guzzo M, **Orlandi E**, Licitra L. "**Management of Salivary Gland Cancer**" (Capitolo 36 da p.625 a 640).In "Head and Neck Cancer: Multimodality Management, 2nd edition". Editor: Jacques Bernier (Springer).2014.

3. Palorini F, Cavallo A, Ferella L, **Orlandi E**. "**Central nervous system (brain, brainstem spinal cord), ear and ocular toxicity**" (capitol 7). In "Modelling Radiotherapy Side Effects: Practical Applications for Planning Optimisation". Editors:Tiziana Rancati and Claudio Fiorino (Taylor & Francis) May 2019.

4.**Orlandi E**, Sanguineti G, Fallai C. "**Radiotherapy for salivary Gland Carcinoma**" (capitolo 11) In "Salivary Gland Cancer" Editors: Laura Locati and Lisa Licitra (Springer) 2019.

5. **Orlandi E, Romanello D, Galbiati D, Licitra L**. "**Radiotherapy and Medical Treatment**" (capitolo xx). In "Pathology of Sinonasal Tumors and tumor-like lesions" Editors: Alessandro Franchi (Springer).

6. **Orlandi E**, Iacovelli NA, Ingargiola R, Ferrari A, Resteghini C, Licitra L, Nicolai P. "**Treatment options for recurrent anterior skull base tumors**" (capitolo 11). In "Anterior Skull Base Tumours". Editor: Patrick Bradley and Piero Nicolai (Karger).

Altre pubblicazioni

1.Co-drafter of INFORMATIVA PER IL PAZIENTE SUGLI EFFETTI COLLATERALI DEL TRATTAMENTO RADIANTE NEL DISTRETTO TESTA-COLLO (gruppo di Studio AIRO testa collo) published on line at www.radioterapiaitalia.it

2.Co-drafter in Oral Cavity cancer group and Paranasal sinuses cancers group for the AIOCC "PERCORSO DIAGNOSTICO, TERAPEUTICO E ASSISTENZIALE (PDTA) PER I TUMORI DI TESTA E COLLO" , on-line at www.aiocc.it.

Linee guida aiom 2018

Studi clinici: Investigatore principale (2016-2019)

Dal 09-03-2016 ad oggi. "Qualità di vita e funzionamento psicologico nei pazienti affetti da tumore testa collo trattati con intento curativo: studio prospettico multicentrico italiano".

PI e Referente scientifico di studio multicentrico condotto con il Gruppo di studio AIRO Testa-Collo.

Dal 23-02-2017 ad oggi. "Ricerca di fattori prognostici clinici e dosimetrici in una popolazione consecutiva di pazienti affetti da carcinoma del rinofaringe e trattati con radioterapia ad intensità modulata e chemioterapia, studio retrospettivo osservazionale". PI di studio monocentrico.

Dal 16-06-2017 ad oggi. "Monocenter, open label clinical investigation on the treatment with Xonrid®, a medical device for prevention and treatment of radiotherapy-induced dermatitis in breast and head and neck cancer patients receiving curative treatment". PI di studio monocentrico.

Dal 22-11-2017 ad oggi. "Studio, randomizzato, in doppio cieco, controllato verso placebo, in cross-over per valutare l'attività di Aqualief® compresse mucoadesive (un integratore alimentare a base di Carnosina ed Ibisco) nei pazienti che sviluppano xerostomia orale come conseguenza della radioterapia per cancro testa-collo". PI di studio monocentrico.

Dal 27-11-2017 ad oggi. "Il ruolo della Radioterapia nella gestione delle metastasi da carcinoma delle ghiandole salivari: studio retrospettivo multicentrico". PI e Referente scientifico di studio multicentrico condotto con il Gruppo di studio AIRO Testa-Collo.

Dal 27-11-2017 ad oggi. "Reirradiazione nei tumori del distretto testa-collo: Studio retrospettivo multicentrico". PI e Referente scientifico di studio multicentrico condotto con il Gruppo di studio AIRO Testa-Collo.

Dal 06-02-2017 ad oggi. Sperimentatore: "Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer MICROLEARNER". PI: Prof. Valdagni R., Responsabile per Head and neck Cancer

2017-2018 "Progetto NPC portal", membro Steering Committee

Dal 2018 ad oggi "Progetto OPC europeo", membro Steering Committee

Da gennaio 2019: "Ritrattamento radioterapico o chirurgico per recidiva da tumori del rinofaringe" Referente scientifico di studio multicentrico condotto con il Gruppo di studio AIRO Testa-Collo.

Da marzo 2019 "Studio features radiomiche predittive/prognostiche per carcinomi del rinofaringe"

Novembre 2019:co-responsabile evento scientifico internazionale MIBIOC MIBIOC - The way of the microbiota in cancer".